Brief Title: DCC-2812 in Participants With Advanced Genitourinary Cancers

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of Participants with Dose-limiting Toxicities (DLTs)

Primary Outcome 1 - Timeframe: Cycle 1 (28 days)

Primary Outcome 2 - Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Primary Outcome 2 - Timeframe: Up to 42 months

Primary Outcome 3 - Measure: Number of Participants With Dose Reduction

Primary Outcome 3 - Timeframe: Up to 42 months

Primary Outcome 4 - Measure: Interruption

Primary Outcome 4 - Timeframe: N/A

Primary Outcome 5 - Measure: or Discontinuation of Study Drug Due to TEAEs

Primary Outcome 5 - Timeframe: N/A

CONDITION

• Renal Cell Carcinoma
• Urothelial Carcinoma
• Castration-resistant Prostate Cancer

ELIGIBILITY

Key Inclusion Criteria:
* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

- * Able to take oral medication

- * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements

- * Adequate organ function and electrolytes
Key Exclusion Criteria:
* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812

- * Impaired cardiac function

- * Major surgery within 28 days of the first dose of study drug

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Clinical Team

Role: Study Director

Affiliation: Deciphera Pharmaceuticals, LLC

Overall Contact

Name: Clinical Team

Phone: 888-724-3274

Email: [email protected]

LOCATION